Correction for Simonin et al., RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia

PHARMACOLOGY. For the article “RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia,” by Frédéric Simonin, Martine Schmitt, Jean-Paul Laulin, Emilie Laboureyras, Jack H. Jhamandas, David MacTavish, Audrey Matifas, Catherine Mollereau, Patrick Laurent, Marc Parmentier, Brigitte L. Kieffer, Jean-Jacques Bourguignon, and Guy Simonnet, which appeared in issue 2, January 10, 2006, of Proc Natl Acad Sci USA (103:466–471; first published January 3, 2006; 10.1073/pnas.0502090103), the authors note that in Fig. 1B, the position of the bond between the adamantane system and the rest of the RF9 compound is incorrect. The corrected figure and its legend appear below. This error does not affect the conclusions of the article.

Fig. 1.

Screening of RFamide derivatives on hNPFF2R. (A) hNPFF2R membranes were labeled with [¹²⁵I]Tyr-NPFF, and three concentrations of RFamide derivatives were tested in competition experiments. Each concentration was tested in duplicate. Results for the reference and the six most active compounds are shown. Arrowheads indicate compounds that were selected for further characterization. (B) Structures of RF2, RF9, RF48, RF49, and BIBP3226.